MILAN, Nov. 1, 2024 /PRNewswire/ -- Diadem SpA, in partnership with researchers from the University of Texas Medical Branch, led by Prof. Rakez Kayed from the Mitchell Center for Neurodegenerative ...
—Quest to Develop and Market a Lab-developed Test Based on the IP of AlzoSure Predict® in the United States, Extending its Industry-leading Portfolio of Alzheimer's Disease Blood Tests— —Validating ...
—CDP Venture Capital and Panakès Partners Leading Equity Financing in Association with Recent €7.5M European Investment Bank Venture Debt Commitment; Additional Venture Funds Expected to Join Equity ...
—New Funds Intended to Support Analysis of ADNI Databases to Validate and Extend Existing Data Showing AlzoSure ® Predict Accurately Identifies Those Individuals Who Will Progress to Alzheimer's ...
MILAN, May 16, 2022 /PRNewswire/ -- Diadem SpA today announced publication of the results of a clinical validation study of its AlzoSure ® Predict prognostic blood test for Alzheimer's disease (AD).
—Data Presented at CTAD Conference Shows that AlzoSure ® Predict Can Accurately Identify Stage of Cognitive Decline and Predict Whether Individuals Will Progress to Alzheimer's Disease Up to Six Years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback